Project description
Targeting lung cancer’s silent driver
Lung cancer treatments often fall short due to resistance and harsh side effects. Researchers urgently need new ways to outsmart the disease. One promising lead is a mysterious molecule: RP3-340N1.2 a long non-coding RNA found in high levels in lung cancer cells. Supported by the Marie Skłodowska-Curie Actions programme, the syRNAlb project is exploring its role in tumour growth and targeting it with precision. Using human serum albumin nanoparticles, syRNAlb will deliver a one-two punch: combining oligonucleotides that silence RP3-340N1.2 with chemotherapeutics. This smart system aims to stop cancer in its tracks, reduce resistance, and spare healthy cells. The project also equips a young researcher with advanced lab and leadership skills.
Objective
Lung cancer remains the most frequently diagnosed and most lethal cancer, making this disease a huge socio-economic challenge. Therefore, new effective therapeutic approaches are urgently needed.
Long non-coding RNAs (lncRNAs) are versatile molecules that influence crucial pathways in cancer progression. RP3-340N1.2 is a poorly investigated but highly overexpressed lncRNA in lung cancer, suggesting it plays a pivotal role in its progression. The fellow will investigate the role of RP3-340N1.2 in lung cancer and its application in targeted therapy.
SyRNAlb aims to overcome the existing limitations of lung cancer therapy by developing clinically translatable human serum albumin-based nanoparticles (HSA NPs). HSA NPs will release therapeutic oligonucleotides and chemotherapeutics in cells to synergistically reduce the lung cancer burden whilst avoiding the development of drug resistance and detrimental side effects.
SyRNAlb will support Horizon Europe's mission on cancer by increasing the knowledge in lung cancer biology, specifically by characterising the role of the oncogenic lncRNA RP3-340N1.2. Additionally, the fellow will address the Translational European Challenge by developing a cutting-edge therapy based on a novel, stable and scalable albumin nanoformulation that co-delivery chemotherapeutics and oligonucleotides against RP3-340N1.2.
The knowledge generated in syRNAlb will expand our limited understanding of the role of RP3-340N1.2 in lung cancer progression and promote the development of an effective treatment. Furthermore, the expertise and tools generated can be customized for other diseases and other target lncRNAs.
This ambitious multidisciplinary project will promote the candidate's career as a future leader by learning not only novel molecular and cellular biology techniques (in 2D and 3D cultures), nano-bioengineering and bioinformatic techniques, but also training in leadership and clinical transfer.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology
- natural sciences biological sciences genetics RNA
- engineering and technology nanotechnology nano-materials
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-MSCA-2024-PF-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
CB2 1TN CAMBRIDGE
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.